Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 25 , ISSUE 10 ( October, 2021 ) > List of Articles

View Point

Aftermath of COVID-19 and Critical Care in India

Divya Hirolli

Keywords : Antimicrobial resistance, COVID-19, Opportunistic infection

Citation Information : Hirolli D. Aftermath of COVID-19 and Critical Care in India. Indian J Crit Care Med 2021; 25 (10):1173-1175.

DOI: 10.5005/jp-journals-10071-23987

License: CC BY-NC 4.0

Published Online: 21-06-2022

Copyright Statement:  Copyright © 2021; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

The coronavirus disease-2019 (COVID-19) pandemic had overwhelmed the healthcare system and forced many patients to be treated at home with oxygen, antibiotics, and steroids, particularly during the second wave. There was increased misuse of antimicrobials in hospitals as well as unguarded self-prescription of these medications among the common people. We are likely to see an increase in the incidence of antimicrobial resistance (AMR), change in the susceptibility pattern of the organisms causing community-acquired infections, and an increase in opportunistic bacterial, tubercular, viral, and fungal infections.

HTML PDF Share
  1. World Healrth Organization. Available from: https://www.who.int/countries/ind/ [Accessed on June 30, 2021].
  2. Dixit A, Kumar N, Kumar S, Trigun V. Antimicrobial resistance: progress in the decade since emergence of New Delhi metallo-β-lactamase in India. Indian J Community Med 2019;44(1):4–8. DOI: 10.4103/ijcm.IJCM_217_18.
  3. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13(12):1057–1098. DOI: 10.1016/S1473-3099(13)70318-9.
  4. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014;14(8): 742–750. DOI: 10.1016/S1473-3099(14)70780-7. PMID: 25022435.
  5. Garg SK. Antibiotic misuse during COVID-19 pandemic: a recipe for disaster. Indian J Crit Care Med 2021;25(6):617–619. DOI: 10.5005/jp-journals-10071-23862.
  6. Langford BJ, So M, Raybardhan S, Leung V, Soucy JR, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect 2021;27(4):520–531. DOI: 10.1016/j.cmi.2020.12.018.
  7. Garcia-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al.; COVID-19 Researchers Group. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021;27(1):83–88. DOI: 10.1016/j.cmi.2020.07.041. PMID: 32745596; PMCID: PMC7836762.
  8. Vijay S, Bansal N, Rao BK, Veeraraghavan B, Rodrigues C, Wattal C, et al. Secondary infections in hospitalized COVID-19 patients: Indian experience. Infect Drug Resist 2021;14:1893–1903. DOI: 10.2147/IDR.S299774.
  9. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020;71(15):732–739. DOI: 10.1093/cid/ciaa237.
  10. Oldenburg CE, Doan T. Azithromycin for severe COVID 19. Lancet 2020;396(10256):936–937. DOI: 10.1016/S0140-67369(20)31863-8.
  11. Metlay JP, Waterer GW, Long AC. Diagnosis and treatment of adults with community-acquired pneumonia. Am J Respir Crit Care Med 2019;200(7):e45–e67. DOI: 10.1164/rccm.201908-1581ST.
  12. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361(9356):512–519. DOI: 10.1016/S0140-6736(03)12489-0.
  13. Monk JM. Predicting antimicrobial resistance and associated genomic features from whole-genome sequencing. J Clin Microbiol 2019;57(2):e01610–e01618. DOI: 10.1128/JCM.01610-18.
  14. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021;135(5):442–447. DOI: 10.1017/S0022215121000992.
  15. Patil S, Jadhav A. Short course of high-dose steroids for anaphylaxis caused flare up of tuberculosis: a case report. J Transl Int Med 2019;7(1):39–42. DOI: 10.2478/jtim-2019-0008.
  16. Jain VK, Iyengar KP, Samy DA, Vaishya R. Tuberculosis in the era of COVID-19 in India. Diabetes Metab Syndr 2020;14(5):1439–1443. DOI: 10.1016/j.dsx.2020.07.034.
  17. Behera D. Tuberculosis, COVID-19 and the end tuberculosis strategy in India. Lung India 2020;37(6):467–472. DOI: 10.4103/lungindia.lungindia_544_20.
  18. Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond) 2018;18(3):212–218. DOI: 10.7861/clinmedicine.18-3-212.
  19. Cook CH. Cytomegalovirus reactivation in “immunocompetent” patients: a call for scientific prophylaxis. J Infect Dis 2007;196(9): 1273–1275. DOI: 10.1086/522433.
  20. Five Covid patients at Delhi's Ganga Ram Hospital suffered rectal bleeding due to CMV infection, one dies. Times of India; June 29, 2021. Available from: https://timesofindia.indiatimes.com/city/delhi.
  21. Kennedy PGE. An overview of viral infections of the nervous system in the immunosuppressed. J Neurol 2020;268:3026–3030. DOI: 10.1007/s00415-020-10265-z.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.